Suppr超能文献

T1和T2期结直肠癌中无肿瘤芽生与低级别肿瘤芽生的预后及淋巴结转移比较

Comparison of the prognosis and lymph node metastasis between no tumor budding and low-grade tumor budding in T1 and T2 colorectal cancer.

作者信息

Lee Jong Yoon, Roh Mee Sook, Lee Jong Hoon, Park Seun Ja, Chang Hee Kyung, Jung Seok Won, Kim Ji Hye

机构信息

Division of Gastroenterology, Department of Internal Medicine, Dong-A University College of Medicine, Daesingongwonro 26, Seo-Gu, Busan, 49201, South Korea.

Department of Pathology, Dong-A University College of Medicine, Daesingongwonro 26, Seo-Gu, Busan, 49201, South Korea.

出版信息

Sci Rep. 2025 Jan 2;15(1):212. doi: 10.1038/s41598-024-84035-6.

Abstract

Tumor budding is a significant prognostic factor in colorectal cancer (CRC) management and is graded as follows: 0-4 buds as low, 5-9 buds as intermediate, and > 10 buds as high. However, the specific prognostic difference between cases with 0 buds (BD0) and those with 1-4 buds (BD1) is not well established owing to a lack of comparative studies. This study aimed to examine and compare the rate of lymph node (LN) metastasis and prognosis by distinguishing between BD0 and BD1 within the low-grade category (0-4 buds) of tumor budding in submucosa (T1) and muscularis propria (T2) CRC. We retrospectively identified 223 cases of T1 and T2 CRC underwent surgery from 2015 to 2018 across three medical institutions using medical records. Pathology, including assessing tumor budding, was subsequently reconfirmed, and the recurrence and survival of patients were evaluated up to December 2023. Patients in the BD1 group exhibited a higher T stage than those in the BD0 group, accompanied by significantly increased rates of lymphovascular and perineural invasion. The prevalence of LN metastasis was 14.8%. No significant differences in LN metastasis were observed between the BD0 and BD1 groups. In a multivariate analysis exploring factors associated with LN metastasis, relevant factors included lymphatic invasion, perineural invasion, and ≥ 5 buds. There were no significant differences in 5-year survival and progression free survival rates between the BD0 and BD1 groups (P = 0.971). This study confirmed that there was no significant difference in LN metastasis or prognosis between patients with BD0 and BD1.

摘要

肿瘤芽生是结直肠癌(CRC)治疗中的一个重要预后因素,其分级如下:0 - 4个芽为低级别,5 - 9个芽为中级,>10个芽为高级。然而,由于缺乏对比研究,0个芽(BD0)的病例与1 - 4个芽(BD1)的病例之间的具体预后差异尚未明确确立。本研究旨在通过区分黏膜下层(T1)和固有肌层(T2)CRC肿瘤芽生低级别类别(0 - 4个芽)中的BD0和BD1,来检查和比较淋巴结(LN)转移率和预后。我们使用病历回顾性地确定了2015年至2018年期间在三家医疗机构接受手术的223例T1和T2 CRC病例。随后重新确认包括评估肿瘤芽生在内的病理学情况,并对患者的复发和生存情况进行评估,直至2023年12月。BD1组患者的T分期高于BD0组,同时淋巴管和神经周围侵犯率显著增加。LN转移的发生率为14.8%。BD0组和BD1组之间在LN转移方面未观察到显著差异。在一项探索与LN转移相关因素的多变量分析中,相关因素包括淋巴管侵犯、神经周围侵犯和≥5个芽。BD0组和BD1组之间的5年生存率和无进展生存率无显著差异(P = 0.971)。本研究证实,BD0和BD1患者在LN转移或预后方面没有显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a74/11696688/f3dd0de3f908/41598_2024_84035_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验